Abstract: The invention relates to methods for diagnosing, predicting disease development, disease progression and/or disease outcome, predicting susceptibility to treatment, and/or classification in the context of diseases or disorders of the female reproductive tract, in particular endometriosis, wherein biomarkers of Table 1 are determined, e.g. CCL5 and/or NEAT1. The invention further relates to pharmaceutical products for use in patients stratified according to the methods of the invention and to compositions comprising reagents for the detection of the biomarkers of Table 1 for the diagnosis of diseases or disorders of the female reproductive tract.

Abstract: The invention relates to methods for diagnosing, predicting disease development, disease progression and/or disease outcome, predicting susceptibility to treatment and/or classification in the context of a disease or disorder of the female reproductive tract, wherein JUP alone or in combination with further biomarkers is determined. The invention further relates to pharmaceutical products for use inpatients stratified according to the methods of the invention and to compositions comprising reagents for the detection of the biomarker JUP or of the biomarker JUP and further biomarkers for the diagnosis of a disease or disorder of the female reproductive tract.